Compare Amgen, Inc. (AMGN) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.32 (market cap $75.52B). The key difference: Amgen, Inc. is far larger — about 2.6× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.4%). Which is the better fit depends on your goals.
| AMGN | MDLZ | |
|---|---|---|
Market Cap | $196.12B | $75.52B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $70.75 |
52-Week Low | $271.18 | $51.51 |
Enterprise Value | $241.41B | $95.62B |
Dividend Yield | 2.77% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Mondelez International (MDLZ) trades at $58.83, up 0.91% today, with a bearish technical signal but strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.67. Revenue grew to $38.54B in 2025, though net income margin compressed to 6.64%. Recent news highlights innovation in packaging and new product launches, alongside a stable dividend of $0.50 per share.
The outlook remains positive with a consensus price target of $68.33, implying 16% upside. Key opportunities include resilient snacking demand and strategic innovations, while risks involve margin pressure from input costs and competitive intensity. Institutional sentiment is bullish, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
